Erik Belleville

1.5k total citations
30 papers, 261 citations indexed

About

Erik Belleville is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Erik Belleville has authored 30 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Erik Belleville's work include Advanced Breast Cancer Therapies (22 papers), Breast Cancer Treatment Studies (15 papers) and HER2/EGFR in Cancer Research (13 papers). Erik Belleville is often cited by papers focused on Advanced Breast Cancer Therapies (22 papers), Breast Cancer Treatment Studies (15 papers) and HER2/EGFR in Cancer Research (13 papers). Erik Belleville collaborates with scholars based in Germany, United States and Denmark. Erik Belleville's co-authors include Claus Bo Vöge Christensen, Martin Dufva, Peter A. Fasching, Tanja Fehm, Michael P. Lux, Wolfgang Janni, Andreas Schneeweiß, Volkmar Müller, Diana Lüftner and Hans Tesch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Erik Belleville

24 papers receiving 258 citations

Peers

Countries citing papers authored by Erik Belleville

Since Specialization

Citations

This map shows the geographic impact of Erik Belleville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Belleville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Belleville more than expected).

Fields of papers citing papers by Erik Belleville

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Belleville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Belleville. The network helps show where Erik Belleville may publish in the future.

Co-authorship network of co-authors of Erik Belleville

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Belleville. A scholar is included among the top collaborators of Erik Belleville based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Belleville. Erik Belleville is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study 2025 ·Journal of Cancer Research and Clinical Oncology ·Andreas Schneeweiß, (unknown), Marc Thill, Marion van Mackelenbergh, Frederik Marmé, Hans Tesch, Tanja Fehm, Tjoung‐Won Park‐Simon, Lothar Häberle, (unknown), Oliver Tomé, (unknown), (unknown), Matthias Ruebner, Erik Belleville, D. Wallwiener, Sara Y. Brucker, Andreas D. Hartkopf	0
2	Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer. 2025 ·Journal of Clinical Oncology ·Boris Hadaschik, Gunhild von Amsberg, Ken Herrmann, Axel S. Merseburger, Peter J. Goebell, Erik Belleville, (unknown), Lothar Haeberle, (unknown), Marc‐Oliver Grimm	0
3	Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041) 2023 ·European Journal of Cancer ·Peter A. Fasching, Alexander Hein, Hans‐Christian Kolberg, Lothar Häberle, (unknown), Matthias Rübner, Erik Belleville, Carolin C. Hack, Tanja Fehm, (unknown), Arndt Hartmann, Ramona Erber, (unknown), Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch	25
4	Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare 2023 ·Geburtshilfe und Frauenheilkunde ·Volkmar Müller, Peter A. Fasching, Naiba Nabieva, Tanja Fehm, Marc Thill, Marcus Schmidt, Thorsten Kühn, Maggie Banys‐Paluchowski, Erik Belleville, (unknown), Michael Untch, Hans‐Christian Kolberg, Nadia Harbeck, Bahriye Aktas, Elmar Stickeler, (unknown), Andreas D. Hartkopf, Wolfgang Janni, Nina Ditsch	0
5	378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC) 2023 ·Annals of Oncology ·Manfred Welslau, PA Fasching, Lothar Mueller, Erik Belleville, Lorenz Rieger, (unknown), (unknown), Lothar Häberle, Hans Tesch	4
6	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer 2021 ·Breast Care ·Diana Lüftner, Andreas Hartkopf, Michael P. Lux, Friedrich Overkamp, Hans Tesch, (unknown), (unknown), Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Wolfgang Janni, Tanja Fehm, Hans‐Christian Kolberg, Johannes Ettl, D. Wallwiener, Andreas Schneeweiß, Sara Y. Brucker, Peter A. Fasching	3
7	Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics 2020 ·Geburtshilfe und Frauenheilkunde ·Diana Lüftner, Andreas Schneeweiß, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Wolfgang Janni, Johannes Ettl, Erik Belleville, Florian Schütz, Marc Thill, Jens Huober, Peter A. Fasching, Hans‐Christian Kolberg, (unknown), Manfred Welslau, Friedrich Overkamp, Hans Tesch, Tanja Fehm, Michael P. Lux	7
8	Update Mammakarzinom 2020 Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien 2020 ·Senologie - Zeitschrift für Mammadiagnostik und -therapie ·Diana Lüftner, Andreas Schneeweiß, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Wolfgang Janni, Johannes Ettl, Erik Belleville, Florian Schütz, Marc Thill, Jens Huober, Peter A. Fasching, Hans‐Christian Kolberg, (unknown), Manfred Welslau, Friedrich Overkamp, Hans Tesch, Tanja Fehm, Michael P. Lux	0
9	Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies 2020 ·Geburtshilfe und Frauenheilkunde ·Andreas Schneeweiß, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Erik Belleville, Jens Huober, Marc Thill, Peter A. Fasching, Hans‐Christian Kolberg, (unknown), Manfred Welslau, Friedrich Overkamp, Hans Tesch, Tanja Fehm, Diana Lüftner, Florian Schütz	11
10	Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer 2019 ·Geburtshilfe und Frauenheilkunde ·Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Naiba Nabieva, Florin‐Andrei Taran, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Tanja Fehm, Hans‐Christian Kolberg, Friedrich Overkamp, Andreas Schneeweiß, Hans Tesch	12
11	Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer 2019 ·Geburtshilfe und Frauenheilkunde ·Florian Schütz, Peter A. Fasching, Manfred Welslau, Andreas D. Hartkopf, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Hans‐Christian Kolberg, Friedrich Overkamp, Florin‐Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Tanja Fehm, Andreas Schneeweiß, Volkmar Müller	13
12	Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis 2019 ·TumorDiagnostik & Therapie ·Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Naiba Nabieva, Florin‐Andrei Taran, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Tanja Fehm, Hans‐Christian Kolberg, Friedrich Overkamp, Andreas Schneeweiß, Hans Tesch	1
13	Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer 2019 ·Geburtshilfe und Frauenheilkunde ·Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Hans‐Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin‐Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiß, Tanja Fehm	12
14	Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom 2019 ·Senologie - Zeitschrift für Mammadiagnostik und -therapie ·Florian Schütz, Peter A. Fasching, Manfred Welslau, Andreas D. Hartkopf, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Hans‐Christian Kolberg, Friedrich Overkamp, Florin‐Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Tanja Fehm, Andreas Schneeweiß, Volkmar Müller	0
15	Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer 2018 ·Geburtshilfe und Frauenheilkunde ·Achim Wöckel, Michael P. Lux, Wolfgang Janni, Andreas D. Hartkopf, Naiba Nabieva, Florin‐Andrei Taran, Friedrich Overkamp, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Manfred Welslau, Erik Belleville, Sara Y. Brucker, Florian Schütz, Peter A. Fasching, Tanja Fehm, Andreas Schneeweiß, Hans‐Christian Kolberg	7
16	SERAPHINA – Safety, Efficacy and patient Reported outcomes of Advanced breast cancer Patients: tHerapy management wIth NAb-paclitaxel in daily routine (a non-interventional study) 2016 ·Senologie - Zeitschrift für Mammadiagnostik und -therapie ·PA Fasching, (unknown), Lothar Häberle, Markus Wallwiener, Andreas Schneeweiß, Hans Tesch, Erik Belleville, (unknown), (unknown), S Brücker, (unknown)	0
17	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network 2015 ·Geburtshilfe und Frauenheilkunde ·Peter A. Fasching, Sara Y. Brucker, Tanja Fehm, Friedrich Overkamp, Wolfgang Janni, Markus Wallwiener, Peyman Hadji, Erik Belleville, Lothar Häberle, Florin‐Andrei Taran, Diana Lüftner, Michael P. Lux, Johannes Ettl, Volkmar Müller, Hans Tesch, D. Wallwiener, Andreas Schneeweiß	43
18	4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients. 2013 ·Journal of Clinical Oncology ·Peter A. Fasching, W. Gumbrecht, Tanja Fehm, Lothar Haeberle, Mathias Muth, (unknown), Michael J. Pugia, (unknown), Mark Matzas, (unknown), Matthias W. Beckmann, Peyman Hadji, (unknown), Michael P. Lux, Wolfgang Janni, Andreas Schneeweiß, Erik Belleville, Thomas Decker, Eva‐Maria Grischke, Hans Tesch	3
19	Quantitative microarray pesticide analysis 2004 ·Journal of Immunological Methods ·Erik Belleville, Martin Dufva, Jens Aamand, (unknown), Liselotte Clausen, Claus Bo Vöge Christensen	22
20	Detection of analyte binding to microarrays using gold nanoparticle labels and a desktop scanner 2003 ·Lab on a Chip ·Anpan Han, Martin Dufva, Erik Belleville, Claus Bo Vöge Christensen	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact